RIG-I and Immune Response to Myxoma Virus in Human Macrophages
Author Information
Author(s): Wang Fuan, Gao Xiujuan, Barrett John W., Shao Qing, Bartee Eric, Mohamed Mohamed R., Rahman Masmudur, Werden Steve, Irvine Timothy, Cao Jingxin, Dekaban Gregory A., McFadden Grant
Primary Institution: BioTherapeutics Research Group, Robarts Research Institute, London, Ontario, Canada
Hypothesis
RIG-I mediates the co-induction of tumor necrosis factor (TNF) and type I interferon (IFN) in response to Myxoma virus infection in primary human macrophages.
Conclusion
RIG-I sensing of Myxoma virus infection in primary human macrophages triggers a novel innate defense mechanism that co-induces TNF and type I IFN to restrict viral infection.
Supporting Evidence
- RIG-I was shown to be activated by Myxoma virus infection in primary human macrophages.
- Both TNF and type I IFN were co-induced in response to Myxoma virus infection.
- Knockdown of RIG-I significantly reduced TNF and IFN production in infected macrophages.
- IRF3 and IRF7 were identified as key transcription factors in the signaling pathway activated by RIG-I.
Takeaway
When a virus called Myxoma infects certain immune cells in humans, a special sensor called RIG-I helps the cells produce important signals that fight off the virus.
Methodology
The study involved infecting primary human macrophages with Myxoma virus and measuring the production of TNF and type I IFN, as well as analyzing the signaling pathways involved.
Limitations
The study primarily focused on primary human macrophages and may not fully represent responses in other cell types or in vivo conditions.
Participant Demographics
The study used primary human macrophages derived from peripheral blood mononuclear cells.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website